Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus MD 76R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus MD 76R.
HYPAQUE-M,75% vs MD-76R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
MD-76R is a radiopaque contrast agent that contains iodine, which attenuates X-rays, thereby enhancing the contrast of blood vessels and tissues during radiographic procedures. It functions by increasing the absorption of X-rays in areas where it is present, allowing for visualization of vascular structures and organ perfusion.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
2–4 mL/kg intravenously, maximum 150 mL per procedure.
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
Terminal half-life 1-2 hours; prolonged in renal impairment.
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal; 95% eliminated unchanged in urine within 24 hours; <1% fecal.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent